Patients with hormone receptor-positive tumors who have received or were not eligible to be treated with endocrine-based therapy may also be eligible for treatment with Talzenna.
Talzenna is an inhibitor of the poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair and in the control of programmed cell death. By blocking the activity of PARP, Talzenna prevents cancer cells from repairing their DNA, eventually eliminating them.
Last year, the U.S. Food and Drug Administration (FDA) had already approved Talzenna for the treatment of patients with inherited BRCA-mutated, HER2-negative, locally advanced or metastatic breast cancer.
The new approval was largely based on findings from the open-label, randomized E